Business Description
ICU Medical Inc
NAICS : 339112
SIC : 3841
ISIN : US44930G1076
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.15 | |||||
Equity-to-Asset | 0.49 | |||||
Debt-to-Equity | 0.8 | |||||
Debt-to-EBITDA | 6.73 | |||||
Interest Coverage | 0.47 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 1.63 | |||||
Beneish M-Score | -2.94 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.8 | |||||
3-Year EBITDA Growth Rate | 7.1 | |||||
3-Year FCF Growth Rate | -19 | |||||
3-Year Book Growth Rate | 7.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 2.5 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 51.18 | |||||
9-Day RSI | 45.6 | |||||
14-Day RSI | 45.68 | |||||
6-1 Month Momentum % | -7.28 | |||||
12-1 Month Momentum % | -45.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.53 | |||||
Quick Ratio | 1.06 | |||||
Cash Ratio | 0.53 | |||||
Days Inventory | 177.22 | |||||
Days Sales Outstanding | 27.36 | |||||
Days Payable | 41.74 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | 1.69 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 32.75 | |||||
Operating Margin % | 2.12 | |||||
Net Margin % | -1.31 | |||||
FCF Margin % | 3.21 | |||||
ROE % | -1.41 | |||||
ROA % | -0.67 | |||||
ROIC % | 0.47 | |||||
ROC (Joel Greenblatt) % | 1.93 | |||||
ROCE % | 0.62 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 20.33 | |||||
PE Ratio without NRI | 33.06 | |||||
Shiller PE Ratio | 35.3 | |||||
PEG Ratio | 2.71 | |||||
PS Ratio | 1.04 | |||||
PB Ratio | 1.1 | |||||
Price-to-Free-Cash-Flow | 32.21 | |||||
Price-to-Operating-Cash-Flow | 14.07 | |||||
EV-to-EBIT | 156.84 | |||||
EV-to-Forward-EBIT | 547.29 | |||||
EV-to-EBITDA | 15.13 | |||||
EV-to-Forward-EBITDA | 16.58 | |||||
EV-to-Revenue | 1.7 | |||||
EV-to-Forward-Revenue | 1.68 | |||||
EV-to-FCF | 52.82 | |||||
Price-to-Projected-FCF | 0.98 | |||||
Price-to-DCF (Earnings Based) | 2.86 | |||||
Price-to-DCF (FCF Based) | 2.79 | |||||
Price-to-Median-PS-Value | 0.28 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.15 | |||||
Earnings Yield (Greenblatt) % | 0.64 | |||||
FCF Yield % | 3.08 | |||||
Forward Rate of Return (Yacktman) % | 12.76 |